DNA Treatment Cuts Bad Cholesterol by Nearly 50% Without Statins

A single-dose genetic therapy has lowered LDL cholesterol — the so-called "bad" cholesterol — by close to 50% in early-stage human trials, according to results discussed at cardiology meetings through 2026. The approach does not rely on daily pills. Instead, it edits a single letter of DNA inside liver cells, permanently dialling down the body's own cholesterol-raising machinery.

The target is PCSK9, a gene that produces a protein controlling how efficiently the liver clears LDL particles from the blood. People born with naturally low PCSK9 activity tend to have low cholesterol levels and a markedly reduced lifetime risk of heart attacks — and no obvious health penalty. Researchers have spent more than a decade trying to copy that genetic advantage pharmacologically.

How the editing works

The therapy uses base editing, a refined form of CRISPR that swaps one DNA letter for another without cutting the double helix in two. The editing instructions are packaged inside lipid nanoparticles — the same delivery technology used in mRNA vaccines — and infused intravenously. The particles travel to the liver, where the edit is made in hepatocytes. Once the change is written, the cell's PCSK9 output drops and stays down.

That permanence is the key difference from existing options. Statins must be taken daily. Injectable PCSK9 inhibitors require dosing every few weeks or twice yearly. A successful edit is intended to be a one-time intervention.

What the trial data show

Early clinical work has focused on patients with familial hypercholesterolaemia or established atherosclerotic disease who cannot reach target cholesterol levels on conventional drugs. At higher doses, participants saw:

• LDL cholesterol reductions approaching 50%
• PCSK9 protein levels falling by roughly 60% or more
• Effects sustained across follow-up periods measured in months rather than weeks

Blood-lipid changes appeared within two weeks of infusion and held steady afterwards, consistent with a durable genetic change rather than a fading drug effect.

Safety questions remain open

Trials have reported transient liver enzyme elevations and infusion-related reactions in some participants. Serious cardiovascular events recorded in early cohorts occurred in patients already at high baseline risk, and investigators have generally judged them unrelated to the editing itself — though independent review continues.

The larger uncertainty is time. Gene editing is irreversible. If an unexpected consequence emerges a decade later, there is no way to undo the change. Off-target edits, where the machinery alters an unintended stretch of DNA, remain a theoretical concern that only long-term monitoring can fully address. Regulators are expected to require extended follow-up of treated patients, potentially spanning 15 years.

Who this is for — and who it isn't

This is not a replacement for statins in the general population. Statins are inexpensive, extensively studied and effective for most people. The realistic near-term audience is narrower: patients with inherited cholesterol disorders, those intolerant of statins, and people whose LDL stays dangerously high despite maximal therapy.

Cost is also unresolved. One-time genetic medicines have historically carried prices in the hundreds of thousands of dollars, though developers argue that a single infusion replacing decades of medication could ultimately prove economical for health systems.

Larger, longer trials measuring actual heart attacks and strokes — not just cholesterol numbers — are now under way. Those outcome data, still several years off, will determine whether gene editing becomes a mainstream cardiovascular tool or remains a specialist option for the hardest cases.